ReNeuron : Directorate Change

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that Michael Hunt, an executive director of the Company and its current Chief Financial Officer, has yesterday resigned from the Company in order to pursue other projects. Mr Hunt joined the Board in early 2001 and will remain with the Company until the end of May to facilitate an orderly transition to his successor, when appointed. The Company has initiated a search for Mr Hunt's replacement and a further announcement will be made in due course.

Mr Hunt commented:

"After twenty years at the Company, and with the business now in a much stronger financial position, it is the right time for me to move on to new challenges. I am proud to have contributed to ReNeuron's progression to be one of the leading players in the gene and cell therapy sector, and I wish the Company and colleagues every future success."

Olav Hellebø, Chief Executive Officer, commented:

"With tenures over the years as both CFO and CEO of the Company, Michael has played a key role in the development of ReNeuron into the exciting business that it is today. On behalf of ReNeuron, I would like to thank Michael for his very significant contribution to the Company and wish him well in his future endeavours."

ENDS

Contacts:

ReNeuron	www.reneuron.com/investors
Olav Hellebø, Chief Executive Officer	Via Walbrook PR
Michael Hunt, Chief Financial Officer
Stifel Nicolaus Europe Limited(NOMAD and Joint Broker) Ben Maddison, Stewart Wallace	[phone]
Allenby Capital Limited(Joint Broker)	[phone]
James Reeve/George Payne (Corporate Finance)
Tim Sohal (Sales & Corporate Broking)
Walbrook PR(Media & Investor Relations)	[phone] or [e-mail]
Paul McManus, Alice Woodings	[phone] / [phone]

About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead cell therapy candidate is in clinical development for the blindness-causing disease, retinitis pigmentosa.

ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the brain. The Company also has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make any tissue cells of choice; in-house programmes are focused on treatments for blood cancers and diabetes.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visitwww.reneuron.com